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Abstract
Background: Multimorbidity, the co-existence of two or more (2+) long-term conditions in an individual, is 
common among problem drug abusers. Objective: To delineate the patterns, multimorbidity prevalence, and 
disease severity in patients enrolled in a community-based primary care methadone maintenance treatment 
(MMT) programme. Design: This was a retrospective cohort study (n=274). The comparator group consisted 
of mainstream primary care patients. Electronic medical record assessment was performed using the Cumula-
tive Illness Rating Scale. Results: Prevalence of multimorbidity across 2+ domains was significantly higher 
within the MMT sample at 88.7% (243/274) than the comparator sample at 51.8% (142/274), p<0.001. MMT 
patients were seven times more likely to have multimorbidity across 2+ domains compared with mainstream 
patients (OR 7.29, 95% confidence interval 4.68–11.34; p<0.001). Prevalence of multimorbidity was consis-
tently high across all age groups in the MMT cohort (range 87.8–100%), while there was a positive correlation 
with age in the comparator cohort (r=0.29, p<0.001). Respiratory, psychiatric, and hepatic–pancreatic domains 
were the three most common domains with multimorbidity. Overall, MMT patients (mean±SD, 1.97±0.43) 
demonstrated significantly higher disease severity than mainstream patients (mean±SD, 1.18±0.78), p<0.001. 
Prevalence of moderate disease severity observed in the <45-year MMT age group was 50% higher than the 
≥45-year comparator age group. Conclusions: Prevalence of multimorbidity and disease severity in MMT 
patients was greater than in the age- and sex-matched comparators. Patients with a history of drug abuse require 
co-ordinated care for treatment of their addiction, and to manage and prevent chronic illnesses. Community-
based programmes delivered through primary care help fulfil this need.
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Introduction
Illicit drug use is a worldwide problem, with opioids 
dominating demand for the illicit drugs [1]. Problem 
drug abuse is associated with an increased risk of 
morbidity and mortality compared with the general 
population [2,3]. To date, most studies have focussed 
on the known comorbidities associated with drug abuse, 
such as the effects associated with non-fatal overdose [4], 
Multimorbidity in methadone patients  47
© 2014 The Authors
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2014;4:46–54
cognitive decline [5], hepatitis, dependence, anxiety, 
depression [6], and other mental health issues [7].
There is increasing evidence that multimorbidity, 
the co-existence of two or more long-term conditions 
in an individual [8], is common among problem drug 
abusers [9–12]. Apart from drug abuse issues, other 
medical complications, including mental health issues, 
respiratory and skin conditions, commonly found in 
these underserviced, marginalised populations, also need 
addressing [13]. Increasing multimorbidity predicts not 
only reduced physical functioning but also increased 
hospital admissions, death rates, and healthcare costs [14].
Recent research shows multimorbidity is common 
in substance abusers attending primary care [2], with 
patients more likely to accept offers of on-site integrated 
care for their comorbid conditions through primary care 
facilities, in preference to referral to specialist care [15].
Several pharmacotherapies are available for the 
treatment of heroin addiction [16]. Of these, methadone 
maintenance treatment (MMT) is one of the oldest [17], 
and results in better health and social outcomes for those 
on treatment [18]. Many current MMT clinics do not 
have the capacity to provide comprehensive medical 
care for other comorbidities present at the time of clinic 
visits. Community-based practice may offer an accessible 
alternative [15].
Our study delineates the patterns, prevalence of 
multimorbidity, and disease severity in a marginalised 
population exemplified by patients enrolled in a com-
munity-based MMT programme delivered through 




This study is a retrospective cohort study using electronic 
medical record review of participants attending a primary 
care-based MMT clinic in Western Australia. The clinic 
is part of a large medical centre offering comprehensive 
general practice care. The study population consisted of 
274 patients with a history of opiate addiction attending 
the practice for MMT. All patients attending the clinic over 
a 10-year period (1 Jan 1999 to 1 Oct 2009) were included. 
A comparator group was selected from a cohort of age- 
and sex-matched patients, with no history of drug abuse, 
attending two mainstream general practice clinics in Perth 
over a 6-month period (1 Jul to 31 Dec 2008) [19].
MMT cohort
Patients on the MMT programme were either self-
referred or referred by community drug teams and 
other general practitioners (GPs). No information was 
recorded in the medical notes on the method of refer-
ral. The majority (97.1%) were polysubstance (including 
alcohol and smoking) abusers. Most patients (96.7%) 
were dependent on illicitly obtained opiates, 1.8% were 
dependent on prescribed opiates, and no information 
was available for the remaining 1.5% of patients. Once 
commenced on methadone by the treating GP, patients 
attended a designated pharmacy daily to obtain their 
dose of methadone. Patients were reviewed at least every 
3 months once they were on a stable dose.
Data extraction
A GP and a medically qualified researcher reviewed all 
patient medical records for at least 41 conditions up to 
the date of data extraction (Oct 2009). Each encounter 
was coded using the Cumulative Illness Rating Scale 
(CIRS) [20,21]. Unlike the published guidelines, which 
included “drug abuse” as part of the psychiatric domain, 
we nominated this as a separate category. Hence, for our 
purposes, scores of 0–4 were used to record the presence 
of disease and its severity in each of 14 domains (excluding 
the index condition of drug abuse). Conditions within 
a particular domain were noted to be present only if 
the information in the records suggested the condition 
was ongoing/chronic and then rated according to the 
CIRS. A total score ranging from 0 to 56 was achieved 
for each patient by adding maximum scores for each 
domain. The total score was then divided by the number 
of domains with morbidities to provide a severity index 
for each patient ranging from 0 to 4. Severity ratings 
were defined as 0, none/low; 1, mild; 2, moderate; and 
3/4, severe [19,20].
Definition of multimorbidity
Our definition of multimorbidity was the co-existence 
of two or more (2+) chronic conditions [22] in addition 
to drug abuse.
Statistical analyses
Data were analysed using SPSS v22 (IBM Corporation, 
Armonk, NY, USA). All statistical analyses were tested 
against an alpha level of 0.05 (two-tailed).
Patient characteristics are expressed as means (standard 
deviation of the mean) for continuous variables and 
as frequencies for categorical variables. Patient age 
was calculated as age at year of data extraction (i.e. 
2009). At the time of data extraction, all patients on 
the list were presumed to be living. The prevalence of 
multimorbidity was calculated as the number of patients 
with long-term conditions in 2+ CIRS domains as a 
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Inter-rater reliability
The intraclass correlation coefficient was 0.85 (95% con-
fidence interval [CI] 0.82–0.88) for number of domains 
with morbidities and 0.83 (95% CI 0.79–0.86) for total 
CIRS scores, indicating good inter-rater reliability.
Prevalence of multimorbidity
Figure 1 shows the prevalence of chronic conditions 
with reference to the number of domains. Catego-
rised prevalence of multimorbidity across 2+ domains 
was significantly higher within the MMT sample at 
88.7% (243/274) compared with 51.8% (142/274) in 
the mainstream sample (p<0.001). The prevalence of 
multimorbidity across 3+ domains was also significantly 
higher among MMT patients (67.2%, 184/274) than 
the mainstream sample (30.7%, 84/274) (p<0.001). In 
addition, 30.7% (84/274) of the MMT sample displayed 
multimorbidity in 5+ domains compared with 10.6% 
(18/274) of mainstream patients (p<0.001).
Logistic regression analyses showed that MMT patients 
were over seven times more likely to have multimorbidity 
across 2+ domains compared with mainstream patients 
(OR 7.29, 95% CI 4.68–11.34; p<0.001), and almost 
four times more likely to have multimorbidity across 3+ 
domains (OR 3.60, 95% CI 2.44–5.23; p<0.001).
Figure 2 shows the prevalence of multimorbidity 
across 2+ domains for the MMT and comparator sam-
ples across age groups. The prevalence of multimorbidity 
was consistently high across all age groups in the MMT 
cohort ranging from 87.8% to 100%, while there was a 
moderate positive correlation between age and multi-
morbidity in the comparator sample (r=0.29; p<0.001). 
Moreover, the prevalence of multimorbidity was sig-
nificantly higher in the MMT sample among younger 
patients.
Patterns of multimorbidity
Table 2 displays the prevalence of the five most common 
domain combinations across 1, 2+, and 3+ domains 
overall and stratified by age for the MMT and compara-
tor samples.
Severity index
Overall, the MMT patients demonstrated significantly 
higher severity (mean±SD) than mainstream patients 
(1.97±0.43 versus 1.18±0.78; p<0.001). In total, 91% 
(249/274) of the MMT cohort were within the moder-
ate or severe categories compared with 32.5% (89/274) 
of the mainstream sample (p<0.001).
Figure 3 displays severity categories across age 
groups for the two samples. A greater proportion of 
proportion of the total sample. Severity was assessed 
using the CIRS Severity Index score. We also counted 
and compared the number of patients with at least one 
level 3 or 4 score across CIRS domains, as well as the 
number of domains with a level 3 or 4 score per patient 
as additional indicators of disease severity [20]. Disease 
patterns were examined using frequencies for the most 
common domain combinations across 1+, 2+, and 3+ 
domains. Comparisons with age- and sex-matched 
general practice patients were made using independent 
samples t-tests, chi-squared tests, and logistic regression.
Inter-rater reliability between data extractors was 
tested on CIRS scores and number of domains with 
morbidities for 40 randomly selected patients and 
assessed using Cronbach’s alpha.
Ethics
Ethics approval for the study was obtained from The 




Table 1 displays information on the age and sex break-
down for the MMT cohort. For the matched cohorts, 
111 (40.5%) of the 274 patients were also female. The 
mean age of patients was 39.58±8.69 years (range 13–82 
years). Female patients were generally older, with an 
age range of 22–82 years, compared with a range of 
13–60 years for male patients, p=0.007. The preva-
lence of smoking was greater in the MMT cohort (46%, 
126/274) than the comparator cohort (17.5%, 48/274), 
p<0.001.
Table 1 Age and sex distribution for the methadone maintenance 
treatment cohort (n=274).
Sex  n  %
Female  111  40.5
Male  163  59.5
Age (years)  Mean (range)  SD
Overall  39.59 (13–82) 8.69
Male  39.50 (13–60) 8.13
Female  39.71 (22–82) 9.46
Age category (years) n  %
<25  3  1.1
25–44  196  71.5
45–64  72  26.3
≥65  3  1.1
SD, standard deviation.
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MMT patients were represented in the moderate and 
severe categories than comparator patients for both the 
<45- and ≥45-year-old age groups. The prevalence of 
moderate severity observed in the <45-year-old age 
group of the MMT sample was 50% higher than that of 
the <45-year-old comparator group. In addition, 32.1% 
(88/274) of the MMT sample had at least one level 3 or 4 
score across domains compared with 12.4% (34/274) of 
the mainstream cohort (p<0.001). Figure 4 displays the 
frequency trends of number of domains with level 3 or 
4 scores for patients across 2+ domains for both cohorts, 
again revealing greater severity of multimorbidity in the 
MMT sample across all age groups.
Discussion
The need for research into the multiple conditions 
affecting substance abusers is known [9–12]; however, 
focus to date has been on specific drug-related conditions 
[4–7], with little attention given to the cumulative and 
synergistic effects of these and other conditions.
This is the first study to assess 41 co-occurring 
conditions affecting 14 anatomical domains to estimate 
patterns and prevalence of multimorbidity among 
patients attending a designated, primary care-run, 
MMT service. Like our earlier mainstream practices [19] 














Number of CIRS domains affected
MMT (n=274)
Mainstream (n=274)
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Figure 1 Prevalence of chronic conditions across domains in the methadone maintenance treatment (MMT) and mainstream cohorts. Numbers 




























Figure 2 Prevalence of multimorbidity in 2+ domains according to age category in the methadone maintenance treatment (MMT) and 
mainstream cohorts. Symbols represent means with 95% confidence intervals in parentheses.
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Figure 3 Distribution of patients according to severity index and age category in the methadone maintenance treatment (MMT) and mainstream 
cohorts. Numbers on the bars represent the number of patients within each group. *p<0.05 for chi-square test for MMT versus mainstream.
Table 2 Prevalence of the five most common domain combinations for 1, 2+ and 3+ domains overall, and stratified for age in the methadone main-
tenance treatment (MMT) cohort.
Number 
of domains






Age category (MMT only), % (n)
<25 years 25–44 years  45–64 years ≥65 years
1  Respiratory  64.6 (177)** 25.2 (69)  66.7 (2)  64.8 (127)  65.3 (47)  33.3 (1)
 Psychiatric (excluding drug abuse)  64.2 (176)** 24.1 (66)  33.3 (1)  63.8 (125)  66.7 (48)  66.7 (2)
 Hepatic–pancreatic  45.3 (124)** 1.5 (4)  0  39.3 (77)  65.3 (47)  0
 Musculoskeletal  39.1 (107)  31.8 (87)  33.3 (1)  34.2 (67)  50.0 (36)  66.7 (2)
 Lower gastrointestinal  25.6 (70)**  12.0 (33)  0  24.0 (47)  27.8 (20)  33.3 (1)
2+  Psychiatric + Respiratory  48.6 (118)** 9.9 (14)  33.3 (1)  42.3 (83)  45.8 (33)  33.3 (1)
 Respiratory + Hepatic–pancreatic  35.4 (86)**  1.4 (2)  0  28.6 (56)  41.7 (30)  0
 Psychiatric + Hepatic–pancreatic  35.4 (86)**  0.7 (1)  0  28.1 (55)  43.1 (31)  0
 Psychiatric + Musculoskeletal  32.5 (79)**  14.1 (20)  33.3 (1)  25.5 (50)  37.5 (27)  33.3 (1)
 Respiratory + Musculoskeletal  25.5 (62)  19.0 (27)  33.3 (1)  19.4 (38)  31.9 (23)  0
3+  Psychiatric + Respiratory + Hepatic–pancreatic  33.7 (62)**  0  0  21.4 (42)  27.8 (20)  0
 Psychiatric + Respiratory + Musculoskeletal  27.7 (51)**  2.4 (2)  33.3 (1)  14.8 (29)  29.2 (21)  0
 Psychiatric + Hepatic–pancreatic + Musculoskeletal  20.1 (37)**  1.2 (1)  0  10.7 (21)  22.2 (16)  0
 Psychiatric + Musculoskeletal + Lower gastrointestinal 16.3 (30)*  3.6 (3)  33.3 (1)  8.7 (17)  15.3 (11)  33.3 (1)
 Psychiatric + Respiratory + Lower gastrointestinal  15.8 (29)*  3.6 (3)  33.3 (1)  8.7 (17)  15.3 (11)  0
For 1 domain, denominator MMT (n=274), denominator mainstream (n=274).
For 2+ domains, denominator MMT (n=243), denominator mainstream (n=142).
For 3+ domains, denominator MMT (n=184), denominator mainstream (n=84).
*Chi-squared test significant at 0.05 level vs. mainstream practice.
**Chi-squared test significant at 0.001 level vs. mainstream practice.
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severity to enhance the overall picture of multimorbidity 
burden in this population [20].
The importance of disease burden cannot be 
underestimated. Government and policymakers are 
guided by disease distributions and population health 
impacts in making health service planning decisions at 
regional, national or international levels. Poor quality 
and reporting of findings means that though the global 
burden of disease associated with drug abuse has been 
identified, many studies have not been included in the 
comparative risk assessment, hence, the full impact is not 
evident [24].
Our results suggest that the prevalence of 
multimorbidity and the disease burden amongst the 
MMT group were greater than their age- and sex-
matched general practice counterparts. Of the patients 
on MMT, 88.7% have multimorbidity and 90% have 
moderate to severe disease. This aligns with overseas 
estimates of 91% multimorbidity in a comparable 
cohort [2]. Results also showed that those on MMT 
were seven times more likely to have multimorbidity 
across 2+ domains and four times more likely to have 
multimorbidity across 3+ domains. Increased severity 
was reflected in the higher number and greater frequency 
of domains with level 3 and 4 scores.
Multimorbidity in the MMT cohort was consistently 
higher across age groups. This contrasts with findings 
from the comparator group where multimorbidity was 
positively correlated with age and with our [19] and 
other [25,26] previously published results. The S-shaped 
curve described by Fortin et al. [25] and Brett et al. [19] 
is replaced in the MMT cohort with a consistently high 
plateau distribution.
The prevalence of moderate disease severity observed 
in the <45-year-old MMT group was 50% higher than 
the ≥45-year-old comparator group and higher than that 
reported for a similarly aged cohort of patients attending 
a street health service [23]. It is inevitable that given 
the earlier age of onset, increased severity at an earlier 
































Figure 4 Frequency trends of number of domains with level 3 or 4 scores (moderate/severe rating) according to age category in the methadone 
maintenance treatment (MMT) and mainstream cohorts.
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a lifetime increase in direct cost to the health budget 
(specialist review, emergency department presentations, 
intensive care admissions) and direct and indirect costs 
to the economy (absenteeism, unemployment, and 
welfare payments).
The high prevalence of respiratory, psychiatric 
(not including drug abuse), and hepatic–pancreatic 
morbidity was not unexpected, and has been reported 
in other studies in drug-abusing populations [2,3,9]. 
Respiratory problems are known to be prevalent 
in mental health patients in the community [27]. 
Some comorbid conditions may be a direct result 
of drug abuse [28]. Nearly half of the MMT cohort 
were smokers, which may also account for the high 
prevalence of respiratory conditions. Similarly, increases 
in the respiratory, psychiatric, and musculoskeletal/skin 
morbidities have been reported in homeless populations 
[23,29]. The link between marginalisation through 
low socioeconomic position and multimorbidity and its 
early onset is also known [30–33]. The high prevalence 
found in the current study may thus be attributable 
to poor living standards or homelessness; however, 
socioeconomic demographics were not collected for the 
study.
Patients with a history of drug abuse require 
co-ordinated care to manage and prevent chronic 
illnesses. Methadone-treated patients have shown a 
preference to move from fragmented models of care 
(methadone only) to more integrated approaches where 
comprehensive primary medical care services are 
available [15,34]. Evidence shows that where drug abuse 
treatment and primary medical care services are more 
integrated, other chronic conditions are more likely to 
be identified [33], the adherence to treatment is higher 
[34], treatment benefits are better [13], and admissions 
to hospital and presentations to emergency departments 
are reduced [13,35]. Many current MMT-only clinics do 
not have the capacity to provide comprehensive medical 
care for other comorbidities present at the time of clinic 
visits. Primary care-based co-ordinated care may offer 
an accessible alternative.
Evaluation focussing on clinical outcomes of MMT 
services in different clinical settings highlights the 
importance of expanding MMT services through 
general practice. Not only does this mode of service 
delivery offer potential for maximising attendance by 
reducing the stigma associated with specialist treatment 
clinics, it also offers a more cost-effective option at a 
third of the cost offered through specialist psychiatric 
services [36].
In conclusion, our findings provide preliminary infor-
mation highlighting the presence of multimorbidity 
in drug-affected populations presenting to a commu-
nity-based primary care MMT service and which have 
challenging implications for the design and delivery of 
such healthcare services.
Limitations
Over 47,000 Australians received a pharmacotherapy 
treatment in 2013, of whom 67% were treated with 
MMT [37]. Our study focussed on a cohort of 247 
patients, which is a small representation at a national level 
(more especially after taking into account the systematic 
differences that have been reported between clinical 
settings [36]). Larger follow-up studies of sufficient 
statistical power therefore need to be undertaken at a 
national level to obtain the true profile of multimorbidity 
in this marginalised group.
With regard to age distribution, there were only three 
patients in each of the age categories <25 years and ≥65 
years. Age stratification for the majority of analyses was 
undertaken on <45- and ≥45-year age groups.
Definite information on polydrug abuse or length of 
time on MMT was not recorded or taken into account 
in analyses.
Samples were drawn from different catchment areas with 
differences in the index of socioeconomic advantage and 
disadvantage. We did not directly record socioeconomic 
status. Estimates show that the MMT cohort had a lower 
ranking (7th percentile in Western Australia) compared 
with the comparator cohort (85–90th percentile) [38]. 
Whilst the MMT data were collected for patients seen 
over a 10-year period, the comparator mainstream practice 
data were collected for patients seen over 6 months.
Acknowledgements
We acknowledge the assistance of the staff at the Murray 
Medical Centre, Mandurah and the medical practices 
involved in the study. We acknowledge the assistance of 
Dr Agung Riono with data acquisition.
Conflicts of interest
T.B., D.A.R., and L.T. have received research grant 
funding; D.A.R. has received support from research 
donations; R.B. is a treating GP at the methadone clinic. 
There are no other relationships or activities to declare 
that could appear to have influenced the submitted work.
Funding
Research support was received from The Australian 
Commonwealth Government Primary Health Care 
Research Evaluation and Development (PHCRED) 
Multimorbidity in methadone patients  53
© 2014 The Authors
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2014;4:46–54
Strategy Phase 2. The General Practice and Primary 
Health Care Research Unit is partly funded under the 
Collaborative Research Network (CRN) Programme 
Grant from the Australian Government Department of 
Education to the University of Notre Dame Australia. 
We also acknowledge financial support from J. Galvin, 
P. Smyth, L. Ryan, W. Cunningham, W. McKenzie and 
J. McKenzie.
References
1. United Nations Office of Drugs and Crime. World Drug Report 
2012. New York: United Nations; 2012. Available from: http://
www.unodc.org/documents/data-and-analysis/WDR2012/
WDR_2012_web_small.pdf [Last accessed Sep 10, 2014].
2. Cullen W, O’Brien S, O’Carroll A, O’Kelly F, Bury G. Chronic illness 
and multimorbidity among problem drug users: a comparative cross 
sectional pilot study in primary care. BMC Fam Pract 2009;10:25. 
View Item
3. Australian Institute of Health and Welfare (AIHW). Australia’s health 
2010. In: AIHW, editor. Australia’s health series no 12. Cat. No. AUS 
122. Canberra: AIHW; 2010. Available from: http://aihw.gov.au/
WorkArea/DownloadAsset.aspx?id=6442452962 [Last accessed Sep 
18, 2014].
4. Warner-Smith M, Darke S, Day C. Multimorbidity associated with 
non-fatal heroin overdose. Addiction 2002;97:963–7. View Item
5. Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment 
among methadone maintenance patients. Addiction 2000;95:687–
95. View Item
6. National Drug and Alcohol Research Centre Report. Illicit drug use 
in Australia: epidemiology, use patterns and associated harm. 2nd Ed. 
Canberra: Commonwealth of Australia; 2007. Available from: http://
www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.
nsf/Content/17B917608C1969ABCA257317001A72D4/$File/
mono-63.pdf [Last accessed Sep 15, 2014].
7. Arnold-Reed DE, O’Neil P, Holman CDJ, Bulsara MK, Rodiguez C, 
Gawthorne G, et al. A comparison of mental health hospital admis-
sions in a cohort of heroin users prior to and after oral naltrexone 
maintenance. Am J Drug Alcohol Abuse 2007;335:655–64. View Item
8. Mercer SM, Smith SM, Wyke S, O’Dowd T, Watt GC. Multimor-
bidity in primary care: developing the research agenda. Fam Pract 
2009;26:79–80. View Item
9. Mertens J, Lu YW, Parthasarathy S. Medical and psychiatric condi-
tions of alcohol and drug treatment patients in an HMO. Arch Intern 
Med 2003;163:2511–7. View Item
10. Abram K, Teplin L, McClelland G, Dulcan M. Comorbid psychi-
atric disorders in youth in juvenile detention. Arch Gen Psychiatry 
2003;60:1097–108. View Item
11. National Institute on Drug Abuse (NIDA). Treatment providers need to 
be aware that a myriad of health problems often accompany substance 
abuse. November 10, 2003. Available from: http://archives.drugabuse.
gov/newsroom/03/NR11-10.html [Last accessed Sep15, 2014].
12. Kertesz S, Pletcher M, Safford M, Halanyc J, Kirk K, Schumacher 
J, et al. Illicit drug use in young adults and subsequent decline in 
general health: the Coronary Artery Risk Development in Young 
Adults (CARDIA) Study. Drug Alcohol Depend 2007;88:224–33. 
View Item
13. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating 
primary care with addiction treatment: a randomised controlled trial. 
J Am Med Assoc 2001;286:1715–23. View Item
14. France E, Wyke S, Gunn J, Mair F, McClean G, Mercer S. Multimor-
bidity in primary care: a systematic review of prospective cohort 
studies. Br J Gen Pract 2012;62:e297–307. View Item
15. Umbricht-Schneiter A, Ginn D, Pabst K, Bigelow G. Providing med-
ical care to methadone clinic patients: referral vs on-site care. Am J 
Public health 1994;84:207–10. View Item
16. AL S, Dodrill C, Kosten T. Opioid dependence treatment: options 
in pharmacotherapy. Expert Opin Pharmacother 2009;10:1727–40. 
View Item
17. Kleber HD. Methdaone maintenance 4 decades later – thousands of 
lives saved but still controversial. J Am Med Assoc 2008;300:2303–5. 
View Item
18. National Consensus Development Panel. Effective medical treat-
ment of opiate addiction. Panel on Effective Medical Treatment of 
Opiate Addiction. J Am Med Assoc 1998;280:1936–43. View Item
19. Brett T, Arnold-Reed D, Popescu A, Soliman B, Bulsara M, Fine H, 
et al. Multimorbidity in patients attending 2 Australian primary care 
practices. Ann Fam Med 2013;11:535–42. View Item
20. Miller MD, Towers A. A manual of guidelines for scoring the 
Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Pittsburg, 
Pennsylvania: University of Pittsburg; 1991. Available from: http://
www.anq.ch/fileadmin/redaktion/deutsch/20121211_CIRSG_
Manual_E.pdf [Last accessed Sep 15, 2014].
21. Hudon C, Fortin M, Soubhi H. Abbreviated guidelines for scoring 
Cumulative Illness Rating Scale (CIRS) in family practice. J Clin 
Epidemiol 2007;60:212. View Item
22. O’Halloran J, Miller G, Britt H. Definining chronic conditions for 
primary care with ICPC-2. Fam Pract 2004;21:381–6. View Item
23. Brett T, Arnold-Reed D, Troeung L, Bulsara M, Williams A, Moorhead 
R. Multimorbidity in a marginalised, street-health Australian popu-
lation – a retrospective cohort study. BMJ Open 2014;4:e005461. 
View Item
24. Degenhardt L, Whiteford H, Hall W. The Global Burden of Disease 
projects: what have we learned about illicit drug use and dependence 
and their contribution to the global burden of disease? Drug Alcohol 
Rev 2014;33:4–12. View Item
25. Fortin M, Stewart M, Poitra M-E, Almirall J, Maddocks H. A sys-
tematic review of prevalence studies on multimorbidity: toward a 
more uniform methodology. Ann Fam Med 2012;10:142–51. View 
Item
26. Britt H, Miller GC, Charles J, Henderson J, Bayram C, Pan Y, et al. 
General practice activity in Australia 2009–2010. BEACH: Better-
ing the Evaluation And Care of Health. General Practice Series no. 
27. Cat. no. GEP 27. Canberra: AIHW; 2010. Available from: http://
www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442472722 
[Last accessed Sep 18, 2014].
27. Kendrick T. Cardiovascular and respiratory risk factors and symp-
toms among general practice patients with long-term mental illness. 
Br J Psychiatry 1996;169:733–9. View Item
28. National Institute on Drug Abuse (NIDA). Heroin (Research 
Report). NIH Publication No. 14-0165. Available from: http://
www.drugabuse.gov/publications/research-reports/heroin [Last 
accessed May 15, 2014].
29. Hewett N, Hiley A, Gray J. Morbidity trends in the population 
of a specialised homeless primary care service. Br J Gen Pract 
2011;61:200–2. View Item
30. Mercer S, Watt G. The inverse care law: clinical primary care 
encounters in deprived and affluent areas of Scotland. Ann Fam Med 
2007;5:503–10. View Item
31. Shadmi E. Multimorbidity and equity in health. Intl J Equity Health 
2013;12:59. View Item
54  D. E. Arnold-Reed et al.
© 2014 The Authors
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2014;4:46–54
32. Smith S, Ferede A, O’Dowd T. Multimorbidity in younger deprived 
patients: an exploratory study of research and service implications in 
general practice. BMC Fam Pract 2008;9:1–5. View Item
33. Rowe TA, Janet S, Jacapraro JS, Rastegar DA. Entry into primary 
care-based buprenorphine treatment is associated with identification 
and treatment of other chronic medical problems. Addict Sci Clin 
Pract 2012;7:22–6. View Item
34. Selwyn P, Budner N, Wasserman W, Arno P. Utilisation of on-site 
primary care services by HIV-seroposititive and seronegative drug 
users in a methaodone maintenance program. Public Health Rep 
1993;108:492–500.
35. Laine C, Hauck W, Gourevitch M, Cohen A, Turner B. Regular out-
patient medical and drug abuse care and subsequent hospitalization 
of persons who use illicit drugs. J Am Med Assoc 2001;285:2355–62. 
View Item
36. Department of Human Services and Health. Review of methadone 
treatment in Australia. Final Report. Canberra, ACT: Commonwealth 
Government of Australia; 1995. Available from: http://www.health.gov.
au/internet/main/publishing.nsf/Content/C62C471246BB0821CA2
57BF0001ED93B/$File/ndsp7.11.pdf [Last accessed Sep 15, 2014].
37. Australian Institute of Health and Welfare. Drug treatment for opioid 
dependence 2013. Report Profile. Canberra, ACT: Australian Gov-
ernment; 2013. Available from: http://www.aihw.gov.au/WorkArea/
DownloadAsset.aspx?id=60129547321 [Last accessed Sep 15, 2014].
38. Australian Bureau of Statistics. Census of Population and Hous-
ing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2011. 
Australian Bureau of Statistics. Canberra, ACT: Commonwealth 
of Australia; 2013. Available from: http://www.abs.gov.au/AUS-
STATS/abs@.nsf/DetailsPage/2033.0.55.0012011?OpenDocum
ent [Last accessed Sep 15, 2014].
